CoChat
Sign Up
Cited by 46Pharmacogenetics and Drug MetabolismTreatment of Major DepressionGenetic Associations and Epidemiology

Length of Psychiatric Hospitalization is Correlated With CYP2D6 Functional Status in Inpatients with Major Depressive Disorder

Open access
Ruaño, Gualberto, Szarek, Bonnie L, Villagra, David, Gorowski, Krystyna, Kocherla, Mohan, Seip, Richard L, Goethe, John W, Schwartz, Harold I·2013·Biomarkers in Medicine
DOI 10.2217/bmm.13.16PMC PMC4912222
Open this paper in CoChat — free account

Abstract

AIM: This study aimed to determine the effect of the CYP2D6 genotype on the length of hospitalization stay for patients treated for major depressive disorder. METHODS: A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene. Prospectively defined drug metabolism indices (metabolic reserve, metabolic alteration and allele alteration) were determined quantitatively and assessed for their relationship to length of hospitalization stay. RESULTS: Hospital stay was significantly longer in deficient CYP2D6 metabolizers (metabolic reserve <2) compared with functional or suprafunctional metabolizers (metabolic reserve ≥2; 7.8 vs 5.7 days, respectively; p = 0.002). CONCLUSION: CYP2D6 enzymatic functional status significantly affected length of hospital stay, perhaps due to reduced efficacy or increased side effects of the medications metabolized by the CYP2D6 isoenzyme. Functional scoring of CYP2D6 alleles may have a substantial impact on the quality of care, patient satisfaction and the economics of psychiatric treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/bmm.13.16

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Psychiatric morbidity is greater at discharge among psychiatric patients with a shorter length of stay than among those with a longer length of stay.

    “others have indicated that psychiatric morbidity is greater at discharge among psychiatric patients with a shorter LOS than those with a longer LOS (Glick et al., 2011; Ruaño et al., 2013).”

    From Time in treatment: Examining mental illness trajectories across inpatient psychiatric treatment (2020) · cites this paper as Ruaño et al., 2013

    The opening background passage (indexed under Abstract > Conclusion; page not provided) says clinicians have expressed concern that morbidity at discharge may be greater after a brief stay. That supports the direction of the comparison, but the paper presents it as a concern, not an established finding, and does not report a discharge-morbidity comparison from its own study. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • A shorter length of stay predicts a greater risk of readmission.

    “shorter LOS predicts greater risk of readmission (Lin et al., 2006; Ruaño et al., 2013).”

    From Time in treatment: Examining mental illness trajectories across inpatient psychiatric treatment (2020) · cites this paper as Ruaño et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 44 · Cited by 46

Research works printed but not linked: 43

  1. Glick ID Sharfstein SS Schwartz HI Inpatient psychiatric care in the 21st century: the need for reform. Psychiatr. Serv 2011 62 2 206 209 Current overview of the issues and controversies surrounding hospitalization length of stay in mental illness in the USA. 21285100
  2. [3]Rocca P Mingrone C Mongini T Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin. Soc. Psychiatry Psychiatr. Epidemiol 2010 45 6 603 610 19585061
  3. [4]Lin HC Lee HC Psychiatrists’ caseload volume, length of stay and mental healthcare readmission rates: a three-year population-based study. Psychiatry Res 2009 166 1 15 23 19195715
  4. [5]Stellwagen KK Kerig PK Relation of callous–unemotional traits to length of stay among youth hospitalized at a state psychiatric inpatient facility. Child Psychiatry Hum. Dev 2010 41 3 251 261 19949974
  5. [6]McFarland BH Collins JC Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia. Psychiatr. Serv 2011 62 8 871 877 21807824
  6. [8]Park JM Park LT Siefert CJ Abraham ME Fry CR Silvert MS Factors associated with extended length of stay for patients presenting to an urban psychiatric emergency service: a case–control study. J. Behav. Health Serv. Res 2009 36 3 300 308 19089640
  7. [9]Jimenez RE Lam RM Marot M Delgado A Observed-predicted length of stay for an acute psychiatric department, as an indicator of inpatient care inefficiencies. Retrospective case-series study. BMC Health Serv. Res 2004 41 4 15102334 PMC387834
  8. [10]Zhang J Harvey C Andrew C Factors associated with length of stay and the risk of readmission in an acute psychiatric inpatient facility: a retrospective study. Aust. NZ J. Psychiatry 2011 45 7 578 585 PMC3190839 21718126
  9. [11]Chung W Oh SM Suh T Lee YM Oh BH Yoon CW Determinants of length of stay for psychiatric inpatients: analysis of a national database covering the entire Korean elderly population. Health Policy 2010 94 2 120 128 19783062
  10. [12]Bodner E Sarel A Gillath O Iancu I The relationship between type of insurance, time period and length of stay in psychiatric hospitals: the Israeli case. Isr. J. Psychiatry Relat. Sci 2010 47 4 284 290 21270501
  11. [13]Hopko DR Lachar D Bailley SE Varner RV Assessing predictive factors for extended hospitalization at acute psychiatric admission. Psychiatr. Serv 2001 52 10 1367 1373 11585954
  12. [14]Nuyen J Spreeuwenberg PM Groenewegen PP van den Bos GA Schellevis FG Impact of preexisting depression on length of stay and discharge destination among patients hospitalized for acute stroke: linked register-based study. Stroke 2008 39 1 132 138 18063828
  13. [15]Segal SP Preston N Kisely S Xiao J Conditional release in Western Australia: effect on hospital length of stay. Psychiatr. Serv 2009 60 1 94 99 19114577 PMC7609020
  14. [16]Mathers CD Loncar D Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 3 11 e442 17132052 PMC1664601
  15. [17]Glied SA Frank RG Better but not best: recent trends in the well-being of the mentally ill. Health Aff. (Millwood) 2009 28 3 637 648 19414869
  16. [18]Kirchheiner J Brosen K Dahl ML CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand 2001 104 3 173 192 11531654
  17. Kirchheiner J Rodriguez-Antona C Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 2009 23 3 181 191 Pioneering article on CYP2D6genotype-guided dosing of psychotropics. 19320528
  18. Black JL 3rd O'Kane DJ Mrazek DA The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin. Drug Metab. Toxicol 2007 3 1 21 31 Comprehensive, clinically focused treatise on psychotropic drug metabolism and the role of CYP450 pharmacogenetics. 17269892
  19. [21]Rodriguez-Antona C Gurwitz D de Leon J CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost–effectiveness studies. Pharmacogenomics 2009 10 4 685 699 19374522
  20. [22]Bertilsson L Dahl ML Dalen P Al Shurbaji A Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol 2002 53 2 111 122 11851634 PMC1874287
  21. [23]Ruaño G Villagra D Rahim US Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Pers. Med 2008 5 6 579 587 29788619
  22. Kropp S Lichtinghagen R Winterstein K Schlimme J Schneider U Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clin. Lab 2006 52 5–6 237 240 Previous European study addressing the relationships between CYP450 pharmacogenetics and hospitalization length of stay in psychiatry. 16812949
  23. Laika B Leucht S Heres S Steimer W Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost–effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J 2009 9 6 395 403 Previous European study examining the correlations of CYP450 pharmacogenetics with utilization of healthcare resources consequent to psychotropic treatment. 19451914
  24. [26]Swen JJ Wilting I de Goede AL Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther 2008 83 5 781 787 18253145
  25. [27]Hinrichs JW Loovers HM Scholten B van der Weide J Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur. J. Clin. Pharmacol 2008 64 10 979 986 18553077
  26. [28]de Leon J Armstrong SC Cozza KL The dosing of atypical antipsychotics. Psychosomatics 2005 46 3 262 273 15883149
  27. [29]de Leon J Susce MT Johnson M DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009 14 1 19 34 19169185
  28. [30]LLerena A Berecz R Dorado P Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 2003 783 1 213 219 12450541
  29. [31]Berecz R LLerena A De La Rubia A Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 2002 35 6 231 234 12518271
  30. [32]Hendset M Molden E Refsum H Hermann M Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J. Clin. Psychopharmacol 2009 29 6 537 541 19910717
  31. [33]Berecz R Dorado P De La Rubia A Caceres MC Degrell I LLerena A The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets 2004 5 6 573 579 15270204
  32. [34]Dalen P Dahl ML Bernal Ruiz ML Nordin J Bertilsson L 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther 1998 63 4 444 452 9585799
  33. [35]de Leon J Susce MT Pan RM Fairchild M Koch WH Wedlund PJ The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 2005 66 1 15 27 15669884
  34. Hiemke C Baumann P Bergemann N AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011 44 6 195 235 Thorough and recent assessment of the interplay of therapeutic drug monitoring and pharmacogenetics for the major psychotropic classes. 21969060
  35. Villagra D Goethe J Schwartz HI Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomark. Med 2011 5 4 427 438 Previous report from the current authors on the quantitative genotyping methodology for CYP450 genes to derive functional indices in pharmacogenetic research. 21861665 PMC3225004
  36. [38]Gordon J Merante F Weiss S Zastawny R Wong SH Linder MW Valdes R Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine 2006 363 370 AAC Press Washington, DC, USA
  37. [39]Ruaño G Villagra D Szarek B Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomark. Med 2011 5 4 439 449 21861666 PMC3225002
  38. [40]Steimer W Zopf K von Amelunxen S Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem 2004 50 9 1623 1633 15205367
  39. [41]Steimer W Zopf K von Amelunxen S Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem 2005 512 376 385 15590749
  40. [42]Gaedigk A Simon SD Pearce RE Bradford LD Kennedy MJ Leeder JS The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther 2008 83 2 234 242 17971818
  41. de Leon J Arranz MJ Ruano G Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin. Lab. Med 2008 28 4 599 617 Very useful review of practical considerations on the clinical utility of CYP450 genotyping in psychiatry. 19059065
  42. [44]Kirchheiner J Nickchen K Bauer M Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004 9 5 442 473 15037866
  43. [45]Margolis JM O'Donnell JP Mankowski DC Ekins S Obach RS (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab. Dispos 2000 28 10 1187 1191 10997938

Authors
Ruaño, G., Szarek, B. L., Villagra, D., Gorowski, K., Kocherla, M., Seip, R. L., Goethe, J. W., & Schwartz, H. I.
Affiliations
  • Hartford Hospital (US)
  • Genomas (United States) (US)
Corresponding author
Ruaño, Gualberto
ORCID
Venue
Biomarkers in Medicine
Publisher
Informa UK Limited
Published
2013-06
Volume
7
Issue
3
Pages
429-439
ISSN
  • 1752-0363 (ISSN-L)
  • 1752-0371
DOI
10.2217/bmm.13.16
PMC
PMC4912222
OpenAlex
W1982533755
Cited by
46
References
44
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 3 · 2013: 4 · 2012: 1
FWCI
6.56
Type
journal article
Language
en
Open access
Locations
  • Biomarkers in Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1r43mh073291-01)
  • National Institute of Mental Health (R43 MH073291, R44MH073291)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
CYP2D6, major depressive disorder, length of hospital stay, psychiatric inpatients, drug metabolism, CYP2D6 genotype, metabolic reserves, antidepressant efficacy, adverse drug reactions, pharmacogenetics
MeSH terms
Alleles, Major Depressive Disorder, Depressive Disorder, Major, Female, Genotype, Hospitals, Psychiatric, Humans, Inpatients, Length of Stay, Male, Prospective Studies, Cohort Studies, Cytochrome P-450 CYP2D6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review